EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer

Changsong Qi, Lin Shen, Thierry Andre, Hyun Cheol Chung, Timothy L Cannon, Elena Garralda, Antoine Italiano, Damian T Rieke, Tianshu Liu, Domnita-Ileana Burcoveanu, Natascha Neu, Chiara E Mussi und 4 weitere

European Journal of Cancer · 2025-05 · 220 · 115338

DOI: 10.1016/j.ejca.2025.115338 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2025-05. Verfasst von Changsong Qi und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Resea…. Hauptthemen laut MEDLINE: Pyrazoles, Gastrointestinal Neoplasms, Pyrimidines, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesGastrointestinal NeoplasmsPyrimidinesOncogene Proteins, FusionReceptor, trkAProtein Kinase InhibitorsHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overTreatment OutcomeReceptor, trkC

Stichwörter der Autor:innen

Colorectal cancerGastrointestinal cancerLarotrectinibNTRK gene fusionTRK fusion

Substanzen

larotrectinibPyrazolesPyrimidinesOncogene Proteins, FusionReceptor, trkAProtein Kinase InhibitorsReceptor, trkC

Autor:innen und Institutionen

  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing, China. El…
  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing, China.
  • Sorbonne Université and St Antoine Hospital, Paris, France.
  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Inova Schar Cancer Institute, Inova Fairfax Hospital, Fairfax, VA, USA.
  • Early Drug Development Unit, Vall d´Hebron Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

Förderung

  • NCI NIH HHS

Zitieren

APA

Qi, C., Shen, L., Andre, T., Chung, H. C., Cannon, T. L., Garralda, E., Italiano, A., Rieke, D. T., Liu, T., Burcoveanu, D. I., Neu, N., Mussi, C. E., Xu, R. H., Hong, D. S., Drilon, A., & Berlin, J. (2025). Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. European Journal of Cancer, 220, 115338. https://doi.org/10.1016/j.ejca.2025.115338

Vancouver

Qi C, Shen L, Andre T, Chung HC, Cannon TL, Garralda E, et al. Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. European Journal of Cancer. 2025;220:115338. doi:10.1016/j.ejca.2025.115338

BibTeX
@article{Qi2025,
  author = {Qi, Changsong and Shen, Lin and Andre, Thierry and Chung, Hyun Cheol and Cannon, Timothy L and Garralda, Elena and Italiano, Antoine and Rieke, Damian T and Liu, Tianshu and Burcoveanu, Domnita-Ileana and Neu, Natascha and Mussi, Chiara E and Xu, Rui-Hua and Hong, David S and Drilon, Alexander and Berlin, Jordan},
  title = {Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {220},
  pages = {115338},
  doi = {10.1016/j.ejca.2025.115338}
}
Kostenlos starten →